MC-VC-PAB-Azide is a protease-cleavable ADC linker with azide functionality, enabling site-specific antibody conjugation and controlled intracellular drug release, improving therapeutic index and reducing off-target toxicity.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
MC-VC-PAB-Azide is a versatile chemical linker used in various applications within the fields of medicinal chemistry and biotechnology. Here are some key applications of MC-VC-PAB-Azide:
Antibody-Drug Conjugates (ADCs): MC-VC-PAB-Azide is commonly used as a linker in the development of antibody-drug conjugates. This linker connects the cytotoxic drug to the antibody, ensuring precise delivery to tumor cells while minimizing damage to healthy tissues. The azide group allows for a click chemistry reaction, facilitating stable and efficient drug conjugation.
Bioconjugation: In bioconjugation studies, MC-VC-PAB-Azide helps bond biomolecules such as proteins and peptides to various chemical entities. The azide function permits efficient and selective attachment through click chemistry, maintaining biomolecule integrity. This application is pivotal in creating modified biomolecules for drug delivery systems and diagnostics.
Proteomics: In proteomic applications, MC-VC-PAB-Azide is used to tag and identify proteins within complex biological samples. It enables the enrichment and identification of specific proteins through click chemistry reactions with labeled alkyne molecules. This assists researchers in understanding protein interactions and functions in various cellular contexts.
Targeted Drug Delivery: MC-VC-PAB-Azide is instrumental in designing drug delivery systems that target specific cells or tissues. The azide group can be utilized to attach targeting ligands that seek out particular cell types, ensuring localized drug delivery. This enhances therapeutic efficacy and reduces systemic side effects, optimizing treatment outcomes.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01417 | MC-VC-PAB-DMEA-PNU159682 | 1178887-17-6 | |
BADC-00976 | MC-VC-PAB-NH2 | 1616727-20-8 | |
BADC-01845 | MC-VC-PAB-NH2 TFA | 1616727-21-9 | |
BADC-01535 | MC-VC-PAB-Tubulysin M | 1639939-56-2 | |
BADC-00854 | Mc-VC-PAB-SN38 | 1801838-28-7 | |
BADC-00733 | MC-vc-PAB-C6-a-amanitin | ||
BADC-00734 | MC-vc-PAB-DMEA-(PEG2)-duocarmycin SA | ||
BADC-00736 | MC-va-PAB-MMAD | ||
BADC-00739 | MC-vc-PAB-MMAD | ||
BADC-00740 | MC-vc-PAB-Auristatin 0101 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.